

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

**APPOINTMENT OF JOINT COMPANY SECRETARY AND
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND
8.17 OF THE LISTING RULES**

APPOINTMENT OF JOINT COMPANY SECRETARY

The board (the “**Board**”) of directors (the “**Directors**”) of HBM Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) hereby announces that on 9 June 2025, the Board approved the appointment of Ian Yi Liu, Ph.D., J.D., (劉毅) (“**Dr. Liu**”) as a joint company secretary of the Company, with effect from 9 June 2025. Mr. Wing Yat Christopher Lui (“**Mr. Lui**”), the current company secretary of the Company, will be the other joint company secretary of the Company.

The biographical details of Dr. Liu are set out below:

Dr. Liu joined the Company in March 2025 as a Senior Vice President and Global Head of Legal. Since he joined the Company, he has actively interacted with the Board, the executive committee of the Company (the “**EC**”), Chief Executive Officer, President, Chief Finance Officer, Chief Scientific Officer, Chief Strategy Officer, other members of the management, and his colleagues in all functions of the Company. As a result, he became and continues to make himself familiar with the business and operations of Company and the Group, and the industry. Dr. Liu has begun to advise the Company on strategic directions and, upon the EC’s approval, devise and implement such strategies. Since May 2025, Dr. Liu has become the primary contact person of the Company and has been working with the existing company secretary of the Company, Mr. Lui, and communicating with Mr. Lui in the areas including but not limited to the Group’s corporate governance, company secretarial and administrative matters.

Dr. Liu became a member of the Bar in the Commonwealth of Massachusetts, USA in 2006, and has been practicing law ever since. He is registered to practice in the Supreme Judicial Court (the “**SJC**”) of the Commonwealth of Massachusetts, the United States District Court for the District of Massachusetts, the United States Court of Appeal for Veteran Affairs, and the United States Patent and Trademark Offices. In addition, Dr. Liu is a notary public appointed by His Excellency the Governor of the Commonwealth of Massachusetts, USA.

Dr. Liu possesses extensive legal expertise and industry experience in the corporate legal affairs sector. He was the company secretary of Breas Medical Holdings AB, a multinational company with its headquarter in Mölnlycke, Sweden, and subsidiaries in the USA, the United Kingdom, Germany, and China. He also advised the executive management of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a company dually listed on the Stock Exchange (Stock Code: 2196) and the Shanghai Stock Exchange (Stock Code: 600196) (“**Fosun**”), and the boards of directors of several Fosun subsidiaries. As such, he is familiar with corporate governance in multiple jurisdictions, has practical knowledge of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”), and played important roles in managing several boards.

Dr. Liu obtained a Bachelor of Science degree in Chemistry from Fudan University in Shanghai, China, a Ph.D. degree in Chemistry from Worcester Polytechnic Institute in Worcester, MA, US, and a Juris Doctor degree from Suffolk University Law School in Boston, MA, US.

The biographical details of Mr. Lui are set out below:

Mr. Wing Yat Christopher Lui has over ten years of experience in the corporate secretarial field. He has been working for Tricor Services Limited since October 2011. He has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Mr. Lui is currently the sole/joint company secretary of several companies listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), including TOT BIOPHARM International Company Limited (stock code: 1875), TI Cloud Inc. (stock code: 2167) and CARsgen Therapeutics Holdings Limited (stock code: 2171). Mr. Lui received his bachelor’s degree of science in economics and statistics from University College London in the United Kingdom in August 2011. He is a chartered secretary, chartered governance professional and an associate of both The Hong Kong Chartered Governance Institute (HKCGI) and The Chartered Governance Institute in the United Kingdom.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rule 8.17 of the Listing Rules, a listed issuer must appoint a company secretary who meets the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that a listed issuer must appoint as its company secretary an individual who, in the opinion of the Stock Exchange, is capable of discharging the functions of company secretary of the listed issuer by virtue of his/her academic or professional qualifications or relevant experience. Dr. Liu currently does not possess the qualifications of company secretary as required under Rules 3.28 and 8.17 of the Listing Rules. However, the Board considers that Dr. Liu, being the Senior Vice President and Global Head of Legal of the Company, is capable of discharging the functions of a Joint Company Secretary by virtue of his knowledge and experience. Following the appointment of Dr. Liu, Mr. Lui, the current company secretary of the Company who possesses the requisite qualification and experience of a company secretary as required under Rules 3.28 and 8.17 of the Listing Rules, will act as the other joint company secretary of the Company. Dr. Liu and Mr. Lui, as joint company secretaries, will jointly discharge the duties and responsibilities of a company secretary. In relation to the appointment of Dr. Liu as a joint company secretary of the Company, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, a waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a period of three years from the date of Dr. Liu's appointment as a joint company secretary of the Company (the **"Waiver Period"**) on the grounds that the Company will engage Mr. Lui, the other joint company secretary of the Company who possesses the relevant professional qualifications of company secretary required under Rules 3.28 and 8.17 of the Listing Rules, to provide assistance and guidance to Dr. Liu in discharging his duties as one of the joint company secretaries of the Company. This waiver is granted on the conditions that (i) Dr. Liu will be assisted by Mr. Lui during the Waiver Period; and (ii) the waiver could be revoked if there are material breaches of the Listing Rules by the Company. Before the end of the Waiver Period, the Company must demonstrate and seek the Stock Exchange's confirmation that Dr. Liu, having had the benefit of Mr. Lui's assistance during the Waiver Period, has attained the relevant experience and is capable for discharging the functions of company secretary under Rule 3.28 such that a further waiver will not be necessary.

The Board would like to extend its warm welcome to Dr. Liu on his new appointment.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 10 June 2025

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.